Therapeutic Effect of Blueberry Extracts for Acute Myeloid Leukemia
Journal: International Journal of Biopharmaceutical Sciences (Vol.1, No. 1)Publication Date: 2018-01-01
Authors : Colin M McGill Timothy J Brown Yuan-Yin Cheng Lindsey N Fisher Sriram S Shanmugavelandy Sally J Gustafson Kriya L Dunlap Mary Ann Lila Mark Kester Paul T Toran David F Claxton Brian M Barth;
Page : 1-5
Keywords : Acute myeloid leukemia; Blueberry; Mouse models;
Abstract
Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with high incidence in the aging population. In addition, AML is one of the more common pediatric malignancies. Unfortunately, both of these patient groups are quite sensitive to chemotherapy toxicities. Investigation of blueberries specifically as an anti-AML agent has been limited, despite being a prominent natural product with no reported toxicity. In this study, blueberry extracts are reported for the first time to exert a dietary therapeutic effect in animal models of AML. Furthermore, in vitro studies revealed that blueberry extracts exerted anti-AML efficacy against myeloid leukemia cell lines as well as against primary AML, and specifically provoked Erk and Akt regulation within the leukemia stem cell subpopulation. This study provides evidence that blueberries may be unique sources for anti-AML biopharmaceutical compound discovery, further warranting fractionation of this natural product. More so, blueberries themselves may provide an intriguing dietary option to enhance the anti-AML efficacy of traditional therapy for subsets of patients that otherwise may not tolerate rigorous combinations of therapeutics.
Other Latest Articles
- How Experience Shapes Our Health Behaviour
- Clinical Results and Costs of Endovascular Treatment in Comparison with Surgery in Subarachnoid Aneurismatic Hemorrhage (aSAH)
- At What Level Lifestyles Influences Sleep Disorders?
- INVESTIGATING THE EFFECT OF LEXICAL (NON-) EQUIVALENCE ON THE ACQUISITION OF L2 EMOTION TERMS
Last modified: 2018-07-25 18:02:13